Who makes Sacituzumab Govitecan with pegfilgrastim?

Sacituzumab Govitecan with pegfilgrastim is developed by Yeon Hee Park.

What development phase is Sacituzumab Govitecan with pegfilgrastim in?

Sacituzumab Govitecan with pegfilgrastim is in Phase 2.

Last reviewed 2026-04-19 · How we verify

Sacituzumab Govitecan with pegfilgrastim

Yeon Hee Park · Phase 2 active Small molecule

At a glance

Generic name	Sacituzumab Govitecan with pegfilgrastim
Sponsor	Yeon Hee Park
Modality	Small molecule
Phase	Phase 2

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Prevention of Sacituzumab Govitecan-related Neutropenia in Patients With Metastatic Triple Negative Breast Cancer (PHASE2)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Sacituzumab Govitecan with pegfilgrastim CI brief — competitive landscape report
Sacituzumab Govitecan with pegfilgrastim updates RSS · CI watch RSS
Yeon Hee Park portfolio CI